Cargando…

Macrophage-mediated anti-tumor immunity against high-risk neuroblastoma

Neuroblastoma is the most common extracranial childhood solid tumor. The majority of high-risk neuroblastoma is resistant/refractory to the current high intensity therapy. Neuroblastoma lacks classical HLA Class I expression and exhibits low mutation burden, allowing neuroblastoma cells to evade CD8...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tang, Xao X., Shimada, Hiroyuki, Ikegaki, Naohiko
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9232393/ https://www.ncbi.nlm.nih.gov/pubmed/35525858 http://dx.doi.org/10.1038/s41435-022-00172-w

Ejemplares similares

Clinical Relevance of CD4 Cytotoxic T Cells in High-Risk Neuroblastoma
por: Tang, Xao X., et al.
Publicado: (2021)

Genetic and Histopathological Heterogeneity of Neuroblastoma and Precision Therapeutic Approaches for Extremely Unfavorable Histology Subgroups
por: Shimada, Hiroyuki, et al.
Publicado: (2022)

S(+)-ibuprofen destabilizes MYC/MYCN and AKT, increases p53 expression, and induces unfolded protein response and favorable phenotype in neuroblastoma cell lines
por: IKEGAKI, NAOHIKO, et al.
Publicado: (2013)

Local delivery of dinutuximab from lyophilized silk fibroin foams for treatment of an orthotopic neuroblastoma model
por: Ornell, Kimberly J., et al.
Publicado: (2020)

Destabilization of MYC/MYCN by the mitochondrial inhibitors, metaiodobenzylguanidine, metformin and phenformin
por: WANG, STEPHANIE S., et al.
Publicado: (2014)

MYC-family protein overexpression and prominent nucleolar formation represent prognostic indicators and potential therapeutic targets for aggressive high-MKI neuroblastomas: a report from the children’s oncology group
por: Niemas-Teshiba, Risa, et al.
Publicado: (2017)

Anti-tumor effects of rigosertib in high-risk neuroblastoma
por: Radke, Katarzyna, et al.
Publicado: (2021)

Targeting macrophage Syk enhances responses to immune checkpoint blockade and radiotherapy in high-risk neuroblastoma
por: Rohila, Deepak, et al.
Publicado: (2023)

Anti-tumor activity of safranal against neuroblastoma cells
por: Samarghandian, Saeed, et al.
Publicado: (2014)

Augmented expression of MYC and/or MYCN protein defines highly aggressive MYC-driven neuroblastoma: a Children's Oncology Group study
por: Wang, L L, et al.
Publicado: (2015)

Preclinical evaluation of the anti-tumor activity of pralatrexate in high-risk neuroblastoma cells
por: Clark, Rachael A., et al.
Publicado: (2020)

“Re-educating” Tumor Associated Macrophages as a Novel Immunotherapy Strategy for Neuroblastoma
por: Liu, Kevin X., et al.
Publicado: (2020)

Anti-tumor effect of Huaier extract against neuroblastoma cells in vitro
por: Xu, Dong-qing, et al.
Publicado: (2021)

Tumor-associated macrophages promote neuroblastoma via STAT3 phosphorylation and up-regulation of c-MYC
por: Hadjidaniel, Michael D., et al.
Publicado: (2017)

Programming the lymph node microenvironment to enhance anti-tumor T cell immunity in neuroblastoma
por: Gammon, Joshua M, et al.
Publicado: (2015)

4304 Immune markers in tumor immune microenvironment of neuroblastoma correlate with risk groups
por: Gartrell, Robyn Denise, et al.
Publicado: (2020)

Macrophage-Mediated Subversion of Anti-Tumour Immunity
por: Quaranta, Valeria, et al.
Publicado: (2019)

Anti-GD2 Directed Immunotherapy for High-Risk and Metastatic Neuroblastoma
por: Chan, Godfrey Chi-Fung, et al.
Publicado: (2022)

Cryo-thermal therapy induces macrophage polarization for durable anti-tumor immunity
por: He, Kun, et al.
Publicado: (2019)

Exploring and Targeting the Tumor Immune Microenvironment of Neuroblastoma
por: Masih, Katherine E., et al.
Publicado: (2021)

Distinct signatures of the immune responses in low risk versus high risk neuroblastoma
por: Gowda, Madhu, et al.
Publicado: (2011)

PTBP2-Mediated Alternative Splicing of IRF9 Controls Tumor-Associated Monocyte/Macrophage Chemotaxis and Repolarization in Neuroblastoma Progression
por: Tang, Jue, et al.
Publicado: (2023)

Treatment of high-risk neuroblastoma
por: Sung, Ki Woong
Publicado: (2012)

Treatment of High-Risk Neuroblastoma
por: Krystal, Julie, et al.
Publicado: (2023)

Immune Response and Outcome of High-Risk Neuroblastoma Patients Immunized with Anti-Idiotypic Antibody Ganglidiomab: Results from Compassionate-Use Treatments
por: Klingel, Leah, et al.
Publicado: (2022)

Fibroblasts and macrophages cooperate to create a pro-tumorigenic and immune resistant environment via activation of TGF-β/IL-6 pathway in neuroblastoma
por: Louault, Kevin, et al.
Publicado: (2022)

Meta-mining of copy number profiles of high-risk neuroblastoma tumors
por: Depuydt, Pauline, et al.
Publicado: (2018)

Enhanced anti-tumor activity of a new curcumin-related compound against melanoma and neuroblastoma cells
por: Pisano, Marina, et al.
Publicado: (2010)

Immune‐suppressive effects of interleukin‐6 on T‐cell‐mediated anti‐tumor immunity
por: Tsukamoto, Hirotake, et al.
Publicado: (2017)

B cell infiltration is highly associated with prognosis and an immune-infiltrated tumor microenvironment in neuroblastoma
por: Schaafsma, Evelien, et al.
Publicado: (2021)

Immune Monitoring during Therapy Reveals Activitory and Regulatory Immune Responses in High-Risk Neuroblastoma
por: Szanto, Celina L., et al.
Publicado: (2021)

Expression Patterns of Immune Genes Reveal Heterogeneous Subtypes of High-Risk Neuroblastoma
por: Liu, Zhenqiu, et al.
Publicado: (2020)

Childhood survivors of high‐risk neuroblastoma show signs of immune recovery and not immunosenescence
por: Lázničková, Petra, et al.
Publicado: (2020)

Anti-angiogenic SPARC peptides inhibit progression of neuroblastoma tumors
por: Chlenski, Alexandre, et al.
Publicado: (2010)

The Anti-Tumor Activity of the NEDD8 Inhibitor Pevonedistat in Neuroblastoma
por: Foster, Jennifer H., et al.
Publicado: (2021)

Tumor dormancy is closely related to prognosis prediction and tumor immunity in neuroblastoma
por: Tian, Xiangdong, et al.
Publicado: (2023)

Tumor-associated neutrophils and macrophages exacerbate antidrug IgG-mediated anaphylactic reaction against an immune checkpoint inhibitor
por: Arai, Takahiro, et al.
Publicado: (2022)

The genetic landscape of high-risk neuroblastoma
por: Pugh, Trevor J., et al.
Publicado: (2013)

High-Risk Neuroblastoma Treatment Review
por: Smith, Valeria, et al.
Publicado: (2018)

Anti-GRP-R monoclonal antibody antitumor therapy against neuroblastoma
por: Qiao, Jingbo, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_7i13dqjvgg8ho5nfukn0r0il88